Moleculin BiotechMBRX
13F holders, Q3 2024 (September 30)19holders +3
3new positions
0sold out
1famous investor
$2.84avg. 13F price*
At the end of Q3 2024, 19 institutions reported holding Moleculin Biotech Inc. (MBRX) in their 13F filings, up 3 from Q2 2024. 3 opened new positions and 0 sold out. The largest holders were Armistice Capital, LLC ($824K), Vanguard Group Inc. ($203K) and LPL Financial LLC ($103K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Moleculin Biotech Inc.
- CUSIP
- 60855D309
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $61K |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 160,047 shares bought and 13,213 shares sold, net +146,834 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 19 holders
| Armistice Capital, LLC | 0.02% | Add +85.9% | 290,000 | $824K |
| Vanguard Group Inc. | 0.00% | Reduce -15.4% | 71,403 | $203K |
| LPL Financial LLC | 0.00% | Add +7.0% | 36,103 | $103K |
| Geode Capital Management, LLC | 0.00% | Add +10.4% | 21,818 | $62K |
| BlackRock, Inc. | 0.00% | — | 12,475 | $35K |
| Renaissance Technologies | 0.00% | New | 10,996 | $31K |
| Truist Financial Corp. | 0.00% | New | 10,500 | $30K |
| Atticus Wealth Management, LLC | 0.00% | No change | 3,334 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -9.2% | 1,811 | $5K |
| NFSG Corp | 0.00% | No change | 1,367 | $4K |
| Morgan Stanley | 0.00% | Add +5.4% | 449 | $1K |
| Bank of America Corp. | 0.00% | Add +410.7% | 143 | $406 |
| Sandy Spring Bank | 0.00% | No change | 89 | $253 |
| CVA Family Office, LLC | 0.00% | No change | 34 | $97 |
| Osaic Holdings, Inc. | 0.00% | No change | 23 | $65 |
| North Star Investment Management Corp. | 0.00% | No change | 17 | $48 |
| Danske Bank A/S | 0.00% | New | 2 | $6 |
| JPMorgan Chase & Co. | 0.00% | Reduce -83.3% | 1 | $3 |
| Royal Bank of Canada | 0.00% | Reduce -90.0% | 1 | $0 |
"% of holder's portfolio" is MBRX's weight in each manager's 13F, not the share of Moleculin Biotech Inc. the manager owns.